Melanoma (From Cancer Management)

Article

ASYMMETRY

 

Benign
Malignant


BORDER

Benign
Malignant

COLOR

Benign
Malignant

DIAMETER

Benign
Malignant

EVOLVING

Benign
Malignant

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content
The decision from the Ministry of Health, Labour, and Welfare was supported by phase 3 LUNAR trial results showing an OS benefit with Optune Lua in NSCLC.

TTFields Earns Japanese Approval in Unresectable Advanced/Recurrent NSCLC

Roman Fabbricatore
September 15th 2025
Article
Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast
Ateganosine plus cemiplimab was well tolerated in patients with heavily pretreated advanced NSCLC, with most adverse effects grades 1/2 in severity.

Ateganosine Combo Exhibits Favorable Efficacy vs SOC in Advanced NSCLC

Roman Fabbricatore
September 15th 2025
Article
A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 15th 2025
Podcast
All efficacy-evaluable patients with ES-SCLC treated with surufatinib, durvalumab, etoposide, and chemotherapy responded to treatment.

Surufatinib Combo Displays Promising Efficacy in Frontline ES-SCLC

Roman Fabbricatore
September 15th 2025
Article
The second takeaway is that the type of responses and efficacy that we have seen with these combinations rival what we have in our standard of care armamentarium.

How Promising Are Immunotherapy Combos in Indolent Lymphoma?

Tim Cortese
September 15th 2025
Article